News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
867,719 Results
Type
Article (87808)
Company Profile (824)
Press Release (779073)
Multimedia
Podcasts (188)
Webinars (28)
Section
Business (233187)
Career Advice (4144)
Deals (39846)
Drug Delivery (144)
Drug Development (91376)
Employer Resources (203)
FDA (18367)
Job Trends (17415)
News (397758)
Policy (39953)
Tag
Academia (3006)
Academic (2)
Accelerated approval (31)
Adcomms (35)
Allergies (138)
Alliances (56981)
ALS (175)
Alzheimer's disease (1769)
Antibody-drug conjugate (ADC) (315)
Approvals (18518)
Artificial intelligence (585)
Autoimmune disease (140)
Automation (33)
Bankruptcy (406)
Best Places to Work (12634)
BIOSECURE Act (23)
Biosimilars (195)
Biotechnology (488)
Bladder cancer (154)
Brain cancer (62)
Breast cancer (632)
Cancer (4782)
Cardiovascular disease (420)
Career advice (3566)
Career pathing (40)
CAR-T (295)
CDC (59)
Celiac Disease (1)
Cell therapy (795)
Cervical cancer (37)
Clinical research (76690)
Collaboration (1638)
Company closure (5)
Compensation (1093)
Complete response letters (67)
COVID-19 (2983)
CRISPR (94)
C-suite (754)
Cystic fibrosis (148)
Data (5954)
Decentralized trials (2)
Denatured (69)
Depression (134)
Diabetes (502)
Diagnostics (7183)
Digital health (42)
Diversity (12)
Diversity, equity & inclusion (49)
Drug discovery (282)
Drug pricing (209)
Drug shortages (36)
Duchenne muscular dystrophy (228)
Earnings (99915)
Editorial (60)
Employer branding (25)
Employer resources (173)
Events (134630)
Executive appointments (1011)
FDA (21326)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (7)
Frontotemporal dementia (21)
Funding (1459)
Gene editing (205)
Generative AI (60)
Gene therapy (638)
GLP-1 (1095)
Government (5429)
Grass and pollen (8)
Guidances (380)
Healthcare (20941)
HIV (56)
Huntington's disease (45)
IgA nephropathy (80)
Immunology and inflammation (278)
Immuno-oncology (44)
Indications (79)
Infectious disease (3258)
Inflammatory bowel disease (199)
Inflation Reduction Act (16)
Influenza (115)
Intellectual property (227)
Interviews (816)
IPO (17947)
IRA (60)
Job creations (5198)
Job search strategy (2866)
Kidney cancer (17)
Labor market (88)
Layoffs (653)
Leadership (39)
Legal (10155)
Liver cancer (96)
Longevity (14)
Lung cancer (656)
Lymphoma (367)
Machine learning (40)
Management (66)
Manufacturing (770)
MASH (168)
Medical device (14984)
Medtech (15026)
Mergers & acquisitions (22903)
Metabolic disorders (1312)
Multiple sclerosis (153)
NASH (23)
Neurodegenerative disease (327)
Neuropsychiatric disorders (88)
Neuroscience (2994)
NextGen: Class of 2025 (7703)
Non-profit (5103)
Now hiring (62)
Obesity (629)
Opinion (327)
Ovarian cancer (156)
Pain (194)
Pancreatic cancer (211)
Parkinson's disease (278)
Partnered (36)
Patents (480)
Patient recruitment (430)
Peanut (59)
People (66682)
Pharmaceutical (145)
Pharmacy benefit managers (30)
Phase I (23683)
Phase II (33275)
Phase III (25099)
Pipeline (4149)
Policy (324)
Postmarket research (3554)
Preclinical (10671)
Press Release (72)
Prostate cancer (233)
Psychedelics (53)
Radiopharmaceuticals (293)
Rare diseases (829)
Real estate (7437)
Recruiting (80)
Regulatory (28707)
Reports (65)
Research institute (2719)
Resumes & cover letters (651)
Rett syndrome (24)
RNA editing (16)
RSV (82)
Schizophrenia (152)
Series A (244)
Series B (180)
Service/supplier (30)
Sickle cell disease (102)
Special edition (26)
Spinal muscular atrophy (174)
Sponsored (47)
Startups (4328)
State (2)
Stomach cancer (19)
Supply chain (109)
Tariffs (97)
The Weekly (117)
Vaccines (1115)
Venture capital (83)
Weight loss (440)
Women's health (79)
Worklife (21)
Date
Today (11)
Last 7 days (131)
Last 30 days (1854)
Last 365 days (33218)
2026 (28)
2025 (33230)
2024 (38142)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51337)
2018 (39122)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1288)
Alabama (86)
Alaska (7)
Arizona (332)
Arkansas (14)
Asia (51401)
Australia (9025)
California (10953)
Canada (3200)
China (1090)
Colorado (462)
Connecticut (484)
Delaware (330)
Europe (118084)
Florida (1609)
Georgia (354)
Hawaii (3)
Idaho (68)
Illinois (908)
India (63)
Indiana (527)
Iowa (22)
Japan (401)
Kansas (130)
Kentucky (41)
Louisiana (29)
Maine (81)
Maryland (1405)
Massachusetts (8108)
Michigan (345)
Minnesota (637)
Mississippi (6)
Missouri (135)
Montana (34)
Nebraska (28)
Nevada (118)
New Hampshire (81)
New Jersey (2989)
New Mexico (32)
New York (2928)
North Carolina (1545)
North Dakota (10)
Northern California (5178)
Ohio (333)
Oklahoma (22)
Oregon (52)
Pennsylvania (2216)
Puerto Rico (20)
Rhode Island (48)
South America (1656)
South Carolina (61)
South Dakota (1)
Southern California (4209)
Tennessee (169)
Texas (1730)
United States (39838)
Utah (329)
Vermont (1)
Virginia (277)
Washington D.C. (85)
Washington State (929)
West Virginia (4)
Wisconsin (115)
Wyoming (2)
There are 867,719 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
AINGENS MACg Slide Generator
January 2, 2026
·
1 min read
ChemPartner Unveils Updated Visual Identity and Digital Experience Reflecting Its Reputation as a Trusted Biopharma Partner
January 2, 2026
·
2 min read
Mergers & acquisitions
Big Pharma Dealmakers Joined by Spunky Group of Biotech Buyers in Q4
While Novartis secured the biggest deal of the fourth quarter, a handful of riveting tales emerged from the bottom of the M&A list, including a zombie buyout and a bidding war. And no, we’re not talking about Metsera.
January 2, 2026
·
2 min read
·
Annalee Armstrong
Depression
Biohaven Notches Another Psychiatric Failure Months After Key FDA Rejection
The major depressive disorder failure for BHV-7000 is the drug’s second, after Biohaven’s spinocerebellar ataxia treatment troriluzole was rejected by the FDA in November 2025.
January 2, 2026
·
1 min read
·
Annalee Armstrong
Layoff Tracker
Nido Will Close Following Lead Candidate’s Disappointing Phase II Results
Follow along as
BioSpace
tracks job cuts and restructuring initiatives.
January 2, 2026
·
98 min read
·
BioSpace Editorial Staff
Phase III
Ultragenyx Loses $1B in Market Value as Bone Drug Fails To Reduce Fractures
With a pair of Phase III trial flops, Ultragenyx will explore cost reductions as analysts turn attention to an upcoming Angelman syndrome readout.
January 2, 2026
·
2 min read
·
Annalee Armstrong
Drug pricing
Pfizer Leads Industry-Wide Surge in Drug Prices for 2026 Despite Political Pressure
More than a dozen pharmas have recently struck deals with the White House to lower drug prices. Nevertheless, drugmakers reportedly plan to raise the U.S. prices of at least 350 branded medications.
January 2, 2026
·
2 min read
·
Nick Paul Taylor
Approvals
Vanda Ends 40-Year Motion Sickness Drug Drought With FDA Approval for Nereus
Jefferies analysts envision a steady launch curve that could ultimately drive meaningful sales from people who are dissatisfied with existing treatments.
January 2, 2026
·
3 min read
·
Nick Paul Taylor
Complete response letters
FDA Rejects Corcept and Outlook Filings, Crushing Stock Prices
Both companies received agency requests for more evidence of the effectiveness of their therapies.
January 2, 2026
·
2 min read
·
Nick Paul Taylor
Mergers & acquisitions
Five Biggest Biopharma Takeovers of 2025
Four of this year’s biggest acquisitions topped 11-figure figures. One was 2025’s messiest bidding war.
January 2, 2026
·
8 min read
·
Tristan Manalac
1 of 86,772
Next
